Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
14 Αυγ 2024 · The Neo-Real study (GBECAM-0123) is a real-world data effort evaluating patients with TNBC treated with neoadjuvant P + CT in ten cancer centers since July 2020. The objective of this analysis...
29 Μαΐ 2024 · TNBC was defined as per ASCO-CAP guidelines as ER≤1%, PR≤1% and negative HER 2 (0, 1+ by immunohistochemistry, or 2+ ISH negative). Outcomes of interest included event free survival (EFS), overall survival (OS), and pathologic complete response (pCR).
2 Ιουν 2020 · Triple-negative breast cancer (TNBC) accounts for approximately 10–15% of all newly diagnosed breast tumors and is characterized by a lack of expression of the estrogen (ER), progesterone (PgR), and human epidermal growth factor 2 receptors (HER2) [1].
9 Νοε 2021 · Cytotoxic chemotherapy remains the mainstay systemic treatment for early-stage and advanced-stage TNBC 1, although the optimal integration of platinum-based agents remains a matter of debate.
Introduction. Epidemiology and clinical features of triple-negative breast cancer. In recent years, breast cancer (BC) has confidently taken a leading position in the structure of morbidity and mortality from cancer in most countries of Eastern and Western Europe, Asia, and America.
